- - Introduction
Overview
LuciErda 3 mg Tablet
Please fill in the details below, and we’ll get back to you as soon as possible
- - Introduction
Overview
Description
Active Ingredient: Each film-coated tablet contains Erdafitinib 4 mg. Indications: LuciErda is a kinase inhibitor used for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with: Susceptible FGFR3 or FGFR2 genetic alterations, and Disease progression during or after at least one prior platinum-based chemotherapy (including within 12 months of neoadjuvant/adjuvant platinum therapy). Dosage & Administration: Confirm FGFR alterations via testing before starting treatment. The recommended starting dose is 8 mg once daily, taken orally. May be increased to 9 mg daily if predefined criteria are met. Swallow tablets whole, with or without food.
Related Products
Related Posts:
No matching posts found.
Only logged in customers who have purchased this product may leave a review.

Reviews
Clear filtersThere are no reviews yet.